Fed’s Powell opens door to potential rate cuts at Jackson Hole
Mixed movements were observed in the premarket healthcare stocks on Wednesday, with the Health Care Select Sector SPDR Fund (XLV) falling by 0.1%, while the iShares Biotechnology ETF (IBB) rose by 0.2%.
Moderna (NASDAQ:MRNA) experienced a significant increase in value, gaining over 6% after announcing its expectation to add $10 billion to $15 billion in annual sales by 2028. This anticipated surge is tied to the introduction of new products targeting oncology, as well as rare and latent diseases.
Rocket Pharmaceuticals (NASDAQ:NASDAQ:RCKT) also saw a substantial rise, with its value going up more than 39%. This followed their announcement of pricing an underwritten public offering poised to generate gross proceeds of approximately $175 million.
Meanwhile, Mainz Biomed (NASDAQ:MYNZ) reported a climb of over 9% after revealing positive results from a clinical trial. The trial, which assessed the potential inclusion of novel gene expression biomarkers in its colorectal cancer test ColoAlert, showed a sensitivity for the disease of 94%, specificity of 97%, and sensitivity for advanced adenoma of 81%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.